Should Product Differentiation be Restricted?
نویسندگان
چکیده
منابع مشابه
I-14: Assisted Reproduction and Religion What Consideration Should Be and Should Not Be Relevant,
Several important issues are pertinent to an ethical discussion of the new technology today grouped under the name Assisted Reproduction Technology (ART). This is a moral imperative because each of us must decide what is to be considered ethically acceptable in assisted reproduction. Reflecting on the ethical dimension of ‘creating’ a new human life can play a major role in ensuring that in eac...
متن کاملShould the prescription of oral anticancer drugs be restricted?
n the year 2010, the Spanish Society of Medical Oncolgy (SEOM) published an editorial1 in the Annals of Oncology ntitled “Treatment of cancer with oral drugs: a position stateent by the Spanish Society of Medical Oncology”. The main remise of the editorial was a call to grant medical oncologists he exclusive right to prescribe all anticancer drugs, whether dministration is intravenous or oral. ...
متن کاملOrgan donations should not be restricted to relatives.
Should we remove whole organs from living donors only in the case where they are genetically related to the intended recipients of such organs? The practice in a majority of European nations is to apply such a restriction. Yet this restriction obviously limits the availability of already scarce donor organs, and curtails the opportunities for altruistic action on the part of those who, in any g...
متن کاملTuberculosis diagnostics: which target product profiles should be prioritised?
Globally, a third of all tuberculosis (TB) cases are not notified and many patients do not receive drug susceptibility testing (DST) [1]. New diagnostics can contribute to increased case detection, shorter diagnostic delay and reduced TB transmission. While the Xpert MTB/RIF assay (Cepheid Inc., Sunnyvale, CA, USA) is a much needed breakthrough [2], it may not reach lower tiers of the healthcar...
متن کاملShould Pharmaceutical Product Hopping Be Subject to Antitrust Scrutiny?
On September 15, 2014, the New York State Attorney General filed a lawsuit against a brand pharmaceutical manufacturer alleging anticompetitive “product hopping.” The suit alleged that when defendant Actavis executed a “forced switch” of the market for its blockbuster Alzheimer’s drug, Namenda IR, to impel patients to purchase a new version, it engaged in product hopping and violated the Sherma...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Marketing
سال: 1972
ISSN: 0022-2429,1547-7185
DOI: 10.1177/002224297203600302